Meeting Milestones And Patient Needs Through Expedited Delivery Of Phase I Materials

Reneo Pharmaceuticals, a clinical-stage pharmaceutical company, focuses on the development of therapies for patients suffering from genetic mitochondrial disease. Many of Reneo’s patients struggle with day-to-day activities, be that opening a jar or walking across the room. These genetic disorders are mainly present from birth and may be a cause of infant death. Therefore, the company’s aim is to significantly improve these patients' quality of life by improving how their mitochondria work, preserving muscle function, and preventing muscle injury.¹ A key factor in doing this is securing rapid delivery of its product to the patients in need, which required a partner that could provide both product development and clinical packaging services. Reneo found this partner in Thermo Fisher Scientific, which had recently acquired Patheon. Experts from two different sites were able to team up and offer both elements in one proposal and under one contract using Thermo Fisher’s Quick to Clinic™ for Oral Solid Dose program.